Advances From the World Conference on Lung Cancer and New Developments in Relapsed Lymphoma and ImmunotherapyOctober 16th 2019
Emerging from the recent 2019 World Conference on Lung Cancer are several notable developments, Robert L. Ferris, MD, PhD, wrote in this issue of <em>Targeted Therapies in Oncology. </em>
Identification of Certain Tumor Characteristics Enhances Immunotherapy Response in NSCLCOctober 15th 2019
Advances in the development of targeted therapies and the identification of emerging biomarkers of response to treatment have led to an improved ability to predict and enhance responses to immunotherapeutic agents in non–small cell lung cancer.
Patients With Rare Gene Fusion NRG1 Respond to Afatinib in NSCLCOctober 14th 2019
Four patients with lung adenocarcinoma with NRG1 fusions demonstrated some degree of response or tumor stabilization when given afatinib, according to a poster presentation at the 2019 World Conference on Lung Cancer meeting. The findings suggest that the irreversible pan-ERBB inhibitor is a potential treatment in this rare mutation of lung adenocarcinoma.
Treating ALL With Cellular and Targeted Immunotherapies Reduces the Need for TransplantOctober 12th 2019
The advent of an era of targeted immunotherapy and CAR T-cell therapies for the treatment of adult patients with acute lymphoblastic leukemia may reduce the need for hematopoietic stem cell transplant in certain cases.<br />
Patients With Small Cell Lung Cancer Experience Tumor Response With Liposomal IrinotecanOctober 12th 2019
Findings from part 1 of the phase II/III RESILIENT trial of irinotecan hydrochloride liposome injection in second-line treatment of small cell lung cancer showed that for close to 50% of patients, disease control was maintained at 12 weeks. These data were presented at the 2019 World Conference on Lung Cancer.
Expert Reports Mixed Results in Interim Analysis for Multiarm NSCLC TrialOctober 11th 2019
Findings from an interim analysis of the National Lung Matrix Trial, a large, multiarm trial involving patients with non–small cell lung cancer, demonstrated both promising activity and shortcomings in predefined goals in a presentation at the 2019 World Conference on Lung Cancer.